Myocardial InjuryOXAMINCT07772570
Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study)
An observational study of Myocardial Injury and Atherosclerosis Cardiovascular Disease, run by University of Oxford at 1 site in United Kingdom.
Trial summary
Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Myocardial Injury, Atherosclerosis Cardiovascular Disease, Cardiac Imaging Techniques
- What is being tested?
- blood sampling, Intracoronary Imaging and Cardiovascular Magnetic Resonance Imaging
- How many people
- 2,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- May 2012to Dec 2046
- How long will I take part?
- 20 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients presenting with evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND/OR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.
Who may be able to join
- Evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND/OR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.
Who cannot join
- Patients in whom safety or clinical concerns preclude participation.
- Anaemia (Hb <9).
- Pregnant or breast feeding females.
- Additional exclusion criteria for patients undergoing MRI
- claustrophobia which limits / prevents participants from remaining in MRI scanner.
- patients who cannot lie flat on the scan table.
Show all 11Show fewer
- patients with metallic implants, pacemakers, implantable defibrillators etc, unless known to be MRI compatible.
- patients with known allergy to medium of contrast (gadolinium)
- Additional exclusion criteria for patients undergoing coronary CT angiography
- patients with a known allergy to iodinated contrast media
- eGFR< 30 ml/min (stage 3-5 renal disease)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Oxford Heart Centre, John Radcliffe Hospital
Oxford
About this study
Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Sometimes a plaque can suddenly break open, causing a blood clot to form and block the artery. This can lead to a heart attack and permanent damage to the heart muscle.
Although much has been learned about coronary artery disease, important questions remain about why some plaques suddenly become unstable, how this affects blood flow through the smallest blood vessels of the heart, and why some patients develop more heart muscle damage than others.
Read more
The Oxford Acute Myocardial Infarction (OxAMI) research programme aims to improve our understanding of these processes. The investigators will study both the disease within the coronary arteries (the "upstream" problem) and its effects on the heart muscle (the "downstream" damage). By examining these together, the investigators hope to understand more clearly how changes in coronary plaques lead to heart injury and how this differs between patients.
Participants undergoing procedures to investigate or treat coronary artery disease provide an important opportunity to study these processes. During coronary angioplasty (also called percutaneous coronary intervention or PCI), a narrow or blocked artery is opened, usually using a small balloon and a stent. This procedure can disturb the underlying plaque in a similar way to the plaque disruption that occurs during a heart attack. Where appropriate, the investigators may therefore collect blood and material released from the plaque during these procedures. Blood may be collected from different locations in the circulation, allowing the investigators to study substances released by the plaque and heart muscle. Material that would otherwise be discarded during treatment may also be collected for laboratory analysis.
The investigators will use several established and newer techniques to examine the coronary arteries, the small blood vessels within the heart, and the heart muscle. These may include detailed imaging from inside the coronary arteries using intravascular ultrasound (IVUS) or optical coherence tomography (OCT). The investigators may also measure blood pressure and flow within the coronary arteries to assess how well the small blood vessels supplying the heart are working.
Non-invasive heart scans may include cardiovascular magnetic resonance (CMR/MRI), cardiac computed tomography (CT) and echocardiography (ultrasound). These techniques can provide detailed information about the structure and function of the heart, blood supply to the heart muscle, areas of injury or permanent scarring, and changes that occur following a heart attack. In particular, MRI may help distinguish heart muscle that has been permanently damaged from muscle that is injured but could potentially recover after blood flow is restored. This may be especially important for participants who arrive at hospital several hours after their heart attack began.
Other measurements may include electrocardiograms (ECGs), which record the electrical activity of the heart, and measurements of heart pressure, volume and function. Some participants may also have longer-term ECG monitoring.
Blood and tissue samples may be analysed using a range of laboratory techniques. These studies will investigate inflammation, blood clotting and other biological processes involved in coronary artery disease and heart attacks. Newer laboratory methods may allow us to measure large numbers of proteins and small molecules in the blood. Material collected from plaques may also be examined under a microscope to identify its cells and structural components.
With additional consent, blood samples may be stored for genetic research. This could help us understand whether differences in people's genes influence their risk of coronary artery disease, their response to a heart attack, or the amount of heart damage that occurs.
By combining information about coronary plaques, blood flow through the heart's circulation, heart muscle injury, imaging, blood and tissue markers, and genetic factors, the OxAMI study aims to build a detailed picture of coronary artery disease and heart attacks. The programme will establish a carefully characterised group of research participants who may contribute to future OxAMI studies conducted under separate research protocols.
Ultimately, this research aims to identify better ways to predict, diagnose and understand coronary artery disease and heart attacks, and to identify new approaches that could improve treatment and outcomes for future patients.
- Conditions
- Myocardial Injury, Atherosclerosis Cardiovascular Disease, Cardiac Imaging Techniques, Genetics, Thrombus, Trained Immunity
- Being tested
- blood sampling, Intracoronary Imaging, Cardiovascular Magnetic Resonance Imaging, Cardiac Computerised Tomography, Invasive Coronary Physiology
- Medical subject headings
- Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood samplingDiagnostic test
Blood sampling across different periprocedural and follow-up timepoints.
Intracoronary ImagingDiagnostic test
Intracoronary Imaging with approved devices
Cardiovascular Magnetic Resonance ImagingDiagnostic test
Cardiovascular Magnetic Resonance Imaging (Multiparametric Phenotyping)
Cardiac Computerised TomographyDiagnostic test
Photon-counting CT
Invasive Coronary PhysiologyDiagnostic test
Angiography derived, Bolus Thermodilution, Continuous Thermodilution, Doppler Flow
| Study group | Role | What they receive |
|---|---|---|
| Acute Coronary Syndrome | Patients presenting with Acute Coronary syndrome (ST-segment elevation or non-ST-Segment Elevation Receives: Diagnostic Test: blood sampling; Diagnostic Test: Intracoronary Imaging; Diagnostic Test: Cardiovascular Magnetic Resonance Imaging; Diagnostic Test: Cardiac Computerised Tomography; Diagnostic Test: Invasive Coronary Physiology | |
| Stable ischemic heart disease | Patients presenting with suspicion of stable ischemic heart disease Receives: Diagnostic Test: blood sampling; Diagnostic Test: Intracoronary Imaging; Diagnostic Test: Cardiovascular Magnetic Resonance Imaging; Diagnostic Test: Cardiac Computerised Tomography; Diagnostic Test: Invasive Coronary Physiology | |
| Myocardial Injury | Patients presenting with objective evidence of myocardial injury Receives: Diagnostic Test: blood sampling; Diagnostic Test: Intracoronary Imaging; Diagnostic Test: Cardiovascular Magnetic Resonance Imaging; Diagnostic Test: Cardiac Computerised Tomography; Diagnostic Test: Invasive Coronary Physiology | |
| Healthy Controls | Healthy controls Receives: Diagnostic Test: blood sampling; Diagnostic Test: Cardiovascular Magnetic Resonance Imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major adverse cardiovascular events
Composite of cardiac mortality, heart failure, recurrent myocardial infarction, target vessel/lesion revascularization, life threatening arrhythmia
Measured: 20 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2026
- Study startMay 2012
- Primary completionSep 2046 (estimated)
- Study completionDec 2046 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial InjuryStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 20 Years
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Keith M Channon, Principal investigator, University of Oxford
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07772570
- Sponsor's protocol ID
- 10120
- Acronym
- OXAMI
- Status last verified
- Aug 2026
- First submitted
- 14 Aug 2026
- Last updated
- 24 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data may be shared upon reasonable request
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study)
- ClinicalTrials.gov ID
- NCT07772570
- Acronym / sponsor ID
- OXAMI / 10120
- Conditions
- Myocardial Injury, Atherosclerosis Cardiovascular Disease, Cardiac Imaging Techniques, Genetics, Thrombus, Trained Immunity
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Study start
- May 2012 (actual)
- Primary completion
- Sep 2046 (estimated)
- Study completion
- Dec 2046 (estimated)
- First posted
- 19 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Sometimes a plaque can suddenly break open, causing a blood clot to form and block the artery. This can lead to a heart attack and permanent damage to the heart muscle.
Although much has been learned about coronary artery disease, important questions remain about why some plaques suddenly become unstable, how this affects blood flow through the smallest blood vessels of the heart, and why some patients develop more heart muscle damage than others.
The Oxford Acute Myocardial Infarction (OxAMI) research programme aims to improve our understanding of these processes. The investigators will study both the disease within the coronary arteries (the "upstream" problem) and its effects on the heart muscle (the "downstream" damage). By examining these together, the investigators hope to understand more clearly how changes in coronary plaques lead to heart injury and how this differs between patients.
Participants undergoing procedures to investigate or treat coronary artery disease provide an important opportunity to study these processes. During coronary angioplasty (also called percutaneous coronary intervention or PCI), a narrow or blocked artery is opened, usually using a small balloon and a stent. This procedure can disturb the underlying plaque in a similar way to the plaque disruption that occurs during a heart attack. Where appropriate, the investigators may therefore collect blood and material released from the plaque during these procedures. Blood may be collected from different locations in the circulation, allowing the investigators to study substances released by the plaque and heart muscle. Material that would otherwise be discarded during treatment may also be collected for laboratory analysis.
The investigators will use several established and newer techniques to examine the coronary arteries, the small blood vessels within the heart, and the heart muscle. These may include detailed imaging from inside the coronary arteries using intravascular ultrasound (IVUS) or optical coherence tomography (OCT). The investigators may also measure blood pressure and flow within the coronary arteries to assess how well the small blood vessels supplying the heart are working.
Non-invasive heart scans may include cardiovascular magnetic resonance (CMR/MRI), cardiac computed tomography (CT) and echocardiography (ultrasound). These techniques can provide detailed information about the structure and function of the heart, blood supply to the heart muscle, areas of injury or permanent scarring, and changes that occur following a heart attack. In particular, MRI may help distinguish heart muscle that has been permanently damaged from muscle that is injured but could potentially recover after blood flow is restored. This may be especially important for participants who arrive at hospital several hours after their heart attack began.
Other measurements may include electrocardiograms (ECGs), which record the electrical activity of the heart, and measurements of heart pressure, volume and function. Some participants may also have longer-term ECG monitoring.
Blood and tissue samples may be analysed using a range of laboratory techniques. These studies will investigate inflammation, blood clotting and other biological processes involved in coronary artery disease and heart attacks. Newer laboratory methods may allow us to measure large numbers of proteins and small molecules in the blood. Material collected from plaques may also be examined under a microscope to identify its cells and structural components.
With additional consent, blood samples may be stored for genetic research. This could help us understand whether differences in people's genes influence their risk of coronary artery disease, their response to a heart attack, or the amount of heart damage that occurs.
By combining information about coronary plaques, blood flow through the heart's circulation, heart muscle injury, imaging, blood and tissue markers, and genetic factors, the OxAMI study aims to build a detailed picture of coronary artery disease and heart attacks. The programme will establish a carefully characterised group of research participants who may contribute to future OxAMI studies conducted under separate research protocols.
Ultimately, this research aims to identify better ways to predict, diagnose and understand coronary artery disease and heart attacks, and to identify new approaches that could improve treatment and outcomes for future patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 20 Years
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Acute Coronary Syndrome | – | Diagnostic Test: blood sampling, Diagnostic Test: Intracoronary Imaging, Diagnostic Test: Cardiovascular Magnetic Resonance Imaging, Diagnostic Test: Cardiac Computerised Tomography, Diagnostic Test: Invasive Coronary PhysiologyPatients presenting with Acute Coronary syndrome (ST-segment elevation or non-ST-Segment Elevation |
| Stable ischemic heart disease | – | Diagnostic Test: blood sampling, Diagnostic Test: Intracoronary Imaging, Diagnostic Test: Cardiovascular Magnetic Resonance Imaging, Diagnostic Test: Cardiac Computerised Tomography, Diagnostic Test: Invasive Coronary PhysiologyPatients presenting with suspicion of stable ischemic heart disease |
| Myocardial Injury | – | Diagnostic Test: blood sampling, Diagnostic Test: Intracoronary Imaging, Diagnostic Test: Cardiovascular Magnetic Resonance Imaging, Diagnostic Test: Cardiac Computerised Tomography, Diagnostic Test: Invasive Coronary PhysiologyPatients presenting with objective evidence of myocardial injury |
| Healthy Controls | – | Diagnostic Test: blood sampling, Diagnostic Test: Cardiovascular Magnetic Resonance ImagingHealthy controls |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients presenting with evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND/OR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.
Key inclusion criteria (1 listed)
- Evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND/OR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.
Key exclusion criteria (11 listed)
- Patients in whom safety or clinical concerns preclude participation.
- Anaemia (Hb <9).
- Pregnant or breast feeding females.
- Additional exclusion criteria for patients undergoing MRI
- claustrophobia which limits / prevents participants from remaining in MRI scanner.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood samplingBlood sampling across different periprocedural and follow-up timepoints. | Diagnostic test | Acute Coronary Syndrome, Healthy Controls, Myocardial Injury, Stable ischemic heart disease |
| Intracoronary ImagingIntracoronary Imaging with approved devices | Diagnostic test | Acute Coronary Syndrome, Myocardial Injury, Stable ischemic heart disease |
| Cardiovascular Magnetic Resonance ImagingCardiovascular Magnetic Resonance Imaging (Multiparametric Phenotyping) | Diagnostic test | Acute Coronary Syndrome, Healthy Controls, Myocardial Injury, Stable ischemic heart disease |
| Cardiac Computerised TomographyPhoton-counting CT | Diagnostic test | Acute Coronary Syndrome, Myocardial Injury, Stable ischemic heart disease |
| Invasive Coronary PhysiologyAngiography derived, Bolus Thermodilution, Continuous Thermodilution, Doppler Flow | Diagnostic test | Acute Coronary Syndrome, Myocardial Injury, Stable ischemic heart disease |
Primary outcome
Major adverse cardiovascular events
Time frame: 20 years
Composite of cardiac mortality, heart failure, recurrent myocardial infarction, target vessel/lesion revascularization, life threatening arrhythmia
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2026.
- Individual participant dataSharing planned: Yes. Data may be shared upon reasonable request
Related trials for Myocardial Injury
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Not yet recruitingObservational study
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Heart Failure, Coronary Artery Disease
Not yet recruitingPhase 2
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
RecruitingObservational study
Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Keith M Channon principal investigator
University of Oxford
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Injury and Atherosclerosis Cardiovascular Disease, run by University of Oxford at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Keith M Channon, MD (+44 1865 287581, keith.channon@cardiov.ox.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major adverse cardiovascular events (time frame: 20 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026.